Reframing Chronicity with Urgency in Chronic Kidney Disease Management.
作者信息
Neuen Brendon L, Tuttle Katherine R, Bakris George, Vaduganathan Muthiah
机构信息
The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Department of Renal Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.
出版信息
Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1209-1211. doi: 10.2215/CJN.0000000000000526. Epub 2024 Jun 26.
Abstract
摘要
相似文献
1
Reframing Chronicity with Urgency in Chronic Kidney Disease Management.在慢性肾脏病管理中以紧迫性重新审视慢性病状态
Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1209-1211. doi: 10.2215/CJN.0000000000000526. Epub 2024 Jun 26.
2
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂用于患有早期（1至3期）非糖尿病慢性肾病的成人。
Cochrane Database Syst Rev. 2011 Oct 5(10):CD007751. doi: 10.1002/14651858.CD007751.pub2.
3
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂在患有早期（1 至 3 期）非糖尿病慢性肾脏病的成人中的应用。
Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD007751. doi: 10.1002/14651858.CD007751.pub3.
4
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂用于慢性肾脏病和糖尿病患者。
Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588. doi: 10.1002/14651858.CD015588.pub2.
5
Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.用于慢性肾病和糖尿病患者的胰高血糖素样肽1（GLP-1）受体激动剂。
Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.
6
Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.早期转介策略在管理有肾脏疾病标志物的人群中的应用：对临床有效性、成本效益和经济分析证据的系统评价。
Health Technol Assess. 2010 Apr;14(21):1-184. doi: 10.3310/hta14210.
7
Clinical Practice Guideline for detection and management of diabetic kidney disease: A consensus report by the Spanish Society of Nephrology.糖尿病肾病检测与管理临床实践指南：西班牙肾脏病学会共识报告
Nefrologia (Engl Ed). 2025 Apr;45 Suppl 1:1-26. doi: 10.1016/j.nefroe.2025.04.005.
8
Choosing the right calcium channel blocker for patients with hypertension and proteinuric chronic kidney disease.为高血压合并蛋白尿性慢性肾脏病患者选择合适的钙通道阻滞剂。
Curr Med Res Opin. 2025 Jul;41(7):1333-1351. doi: 10.1080/03007995.2025.2544594. Epub 2025 Aug 14.
9
Education programmes for people with chronic kidney disease and diabetes.针对慢性肾脏病和糖尿病患者的教育计划。
Cochrane Database Syst Rev. 2024 Aug 22;8(8):CD007374. doi: 10.1002/14651858.CD007374.pub3.
10
Antioxidants for chronic kidney disease.用于慢性肾病的抗氧化剂。
Cochrane Database Syst Rev. 2012 Oct 17;10(10):CD008176. doi: 10.1002/14651858.CD008176.pub2.
引用本文的文献
1
Risk-directed management of chronic kidney disease.慢性肾脏病的风险导向管理
Nat Rev Nephrol. 2025 May;21(5):287-298. doi: 10.1038/s41581-025-00931-8. Epub 2025 Jan 30.
本文引用的文献
1
Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From 4 Large-Scale Placebo-Controlled Outcome Trials.钠-葡萄糖协同转运蛋白2抑制剂进行心肾保护的时机：来自4项大规模安慰剂对照结局试验的见解
Circulation. 2024 Jul 23;150(4):343-345. doi: 10.1161/CIRCULATIONAHA.124.069382. Epub 2024 May 11.
2
Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Type 2 Diabetes and Chronic Kidney Disease.基于风险加速实施2型糖尿病和慢性肾脏病的指南指导药物治疗
Circulation. 2024 Apr 16;149(16):1238-1240. doi: 10.1161/CIRCULATIONAHA.123.068524. Epub 2024 Apr 15.
3
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.KDIGO 2024慢性肾脏病评估与管理临床实践指南
Kidney Int. 2024 Apr;105(4S):S117-S314. doi: 10.1016/j.kint.2023.10.018.
4
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024.10. 心血管疾病与风险管理：2024年糖尿病护理标准。
Diabetes Care. 2024 Jan 1;47(Suppl 1):S179-S218. doi: 10.2337/dc24-S010.
5
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.估计 2 型糖尿病合并白蛋白尿患者接受 SGLT2 抑制剂、GLP-1 受体激动剂和非甾体类 MRA 联合治疗与常规治疗相比的终生心血管、肾脏和死亡率获益。
Circulation. 2024 Feb 6;149(6):450-462. doi: 10.1161/CIRCULATIONAHA.123.067584. Epub 2023 Nov 12.
6
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).2022 年美国糖尿病协会 (ADA) 和欧洲糖尿病研究协会 (EASD) 共识报告：2 型糖尿病患者高血糖管理。
Diabetes Care. 2022 Nov 1;45(11):2753-2786. doi: 10.2337/dci22-0034.
7
Chronic kidney disease.慢性肾脏病。
Lancet. 2021 Aug 28;398(10302):786-802. doi: 10.1016/S0140-6736(21)00519-5. Epub 2021 Jun 24.
8
Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey.全球各国和地区终末期肾病护理状况：国际横断面调查。
BMJ. 2019 Oct 31;367:l5873. doi: 10.1136/bmj.l5873.
9
Quality of Chronic Kidney Disease Management in Canadian Primary Care.加拿大初级保健中慢性肾脏病管理的质量。
JAMA Netw Open. 2019 Sep 4;2(9):e1910704. doi: 10.1001/jamanetworkopen.2019.10704.
Zotero 插件